NO305083B1 - Risperidonpamoat - Google Patents

Risperidonpamoat

Info

Publication number
NO305083B1
NO305083B1 NO954275A NO954275A NO305083B1 NO 305083 B1 NO305083 B1 NO 305083B1 NO 954275 A NO954275 A NO 954275A NO 954275 A NO954275 A NO 954275A NO 305083 B1 NO305083 B1 NO 305083B1
Authority
NO
Norway
Prior art keywords
pct
sec
compositions
compound
date
Prior art date
Application number
NO954275A
Other languages
English (en)
Norwegian (no)
Other versions
NO954275L (no
NO954275D0 (no
Inventor
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO954275L publication Critical patent/NO954275L/no
Publication of NO954275D0 publication Critical patent/NO954275D0/no
Publication of NO305083B1 publication Critical patent/NO305083B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
NO954275A 1993-04-28 1995-10-26 Risperidonpamoat NO305083B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93201216 1993-04-28
PCT/EP1994/001296 WO1994025460A1 (fr) 1993-04-28 1994-04-22 Pamoate de risperidone

Publications (3)

Publication Number Publication Date
NO954275L NO954275L (no) 1995-10-26
NO954275D0 NO954275D0 (no) 1995-10-26
NO305083B1 true NO305083B1 (no) 1999-03-29

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954275A NO305083B1 (no) 1993-04-28 1995-10-26 Risperidonpamoat

Country Status (32)

Country Link
US (2) US5612346A (fr)
EP (1) EP0697019B1 (fr)
JP (1) JP3478397B2 (fr)
KR (1) KR100307101B1 (fr)
CN (1) CN1041727C (fr)
AT (1) ATE163418T1 (fr)
AU (1) AU675136B2 (fr)
BG (1) BG62004B1 (fr)
CA (1) CA2160366C (fr)
CY (1) CY2107B1 (fr)
CZ (1) CZ286688B6 (fr)
DE (1) DE69408666T2 (fr)
DK (1) DK0697019T3 (fr)
ES (1) ES2113652T3 (fr)
FI (1) FI109125B (fr)
GR (1) GR3026028T3 (fr)
HK (1) HK1006059A1 (fr)
HU (1) HU218212B (fr)
IL (1) IL109448A (fr)
LV (1) LV12315B (fr)
NO (1) NO305083B1 (fr)
NZ (1) NZ266143A (fr)
PH (1) PH30476A (fr)
PL (1) PL182466B1 (fr)
RO (1) RO115955B1 (fr)
RU (1) RU2131428C1 (fr)
SG (1) SG47046A1 (fr)
SI (1) SI9420031B (fr)
SK (1) SK280589B6 (fr)
TW (1) TW376319B (fr)
WO (1) WO1994025460A1 (fr)
ZA (1) ZA942909B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013814A1 (fr) 1993-11-19 1995-05-26 Janssen Pharmaceutica N.V. 1,2-benzisoxazoles et 1,2-benzisothiazoles microencapsules et substitues par 3-piperidinyle
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
AU752552C (en) * 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2221376T3 (es) * 1998-09-30 2004-12-16 ELI LILLY & COMPANY Formulacion de 2-metil-tieno-benzodiazepina.
JP2002529468A (ja) * 1998-11-12 2002-09-10 メルク エンド カムパニー インコーポレーテッド ＧＡＢＡ−Ａα−５逆活性薬の治療性多形およびそのパモエート組成物
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2003250472A1 (en) * 2002-08-23 2004-03-11 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
WO2004094414A1 (fr) * 2003-04-22 2004-11-04 Synthon B.V. Sels hydrosolubles de risperidone
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
AU2004285448C1 (en) * 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
EP2272514A1 (fr) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Utilisation d'une faible dose de pipamperone et d'un deuxième agent actif dans le traitement des maladies neurodégénératives
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2554959A1 (fr) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combinaison d'antagoniste de recepteur nmda et d'inhibiteur mao ou gadpf pour le traitement d'affections liees au systeme nerveux central
PL1838716T3 (pl) * 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
EP1695973A1 (fr) * 2005-02-24 2006-08-30 Neuro3D Sel d'Ocaperidone et composition pharmaceutique le contenant.
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
CA2622758A1 (fr) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Formulations aripiprazoliques nanoparticulaires
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
MX354603B (es) 2007-05-25 2018-03-13 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
SI2234617T1 (sl) * 2007-12-19 2021-07-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
DK3156056T3 (da) 2011-03-18 2024-02-26 Alkermes Pharma Ireland Ltd Farmaceutiske sammensætninger der består af sorbitanestere
PL2702060T3 (pl) * 2011-04-26 2016-06-30 Torrent Pharmaceuticals Ltd Kwasowe addycyjne sole risperidonu i ich kompozycje farmaceutyczne
CA2867121C (fr) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
ES2950418T3 (es) * 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
JP6088637B2 (ja) 2012-04-04 2017-03-01 インターベット インターナショナル ベー． フェー． イソオキサゾリン化合物のための固形経口医薬組成物
CN102659577B (zh) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 一种亚甲基双羟基萘酸的制备方法
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
PL2900270T3 (pl) * 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
MX2016012041A (es) 2014-03-20 2017-01-19 Alkermes Pharma Ireland Ltd Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 可乐定双羟萘酸盐及其制备方法
CA3092335A1 (fr) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Strategie de dosage d'aripiprazole

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
RO115955B1 (ro) 2000-08-30
ZA942909B (en) 1995-10-26
IL109448A0 (en) 1994-07-31
CZ270695A3 (en) 1996-01-17
IL109448A (en) 1997-03-18
AU675136B2 (en) 1997-01-23
JP3478397B2 (ja) 2003-12-15
NO954275L (no) 1995-10-26
CN1041727C (zh) 1999-01-20
DE69408666D1 (de) 1998-04-02
BG100094A (bg) 1996-05-31
SG47046A1 (en) 1998-03-20
TW376319B (en) 1999-12-11
EP0697019B1 (fr) 1998-02-25
FI955166A (fi) 1995-10-27
KR100307101B1 (ko) 2001-11-30
SI9420031B (sl) 2002-08-31
GR3026028T3 (en) 1998-04-30
US5723467A (en) 1998-03-03
SK131395A3 (en) 1996-06-05
HUT72970A (en) 1996-06-28
HU9501934D0 (en) 1995-09-28
FI109125B (fi) 2002-05-31
SK280589B6 (sk) 2000-04-10
HK1006059A1 (en) 1999-02-05
NZ266143A (en) 1996-07-26
JPH08509482A (ja) 1996-10-08
PH30476A (en) 1997-05-28
HU218212B (hu) 2000-06-28
SI9420031A (en) 1996-08-31
RU2131428C1 (ru) 1999-06-10
PL311282A1 (en) 1996-02-05
US5612346A (en) 1997-03-18
CA2160366A1 (fr) 1994-11-10
WO1994025460A1 (fr) 1994-11-10
ES2113652T3 (es) 1998-05-01
AU6721694A (en) 1994-11-21
CA2160366C (fr) 2006-06-06
CY2107B1 (en) 2002-04-26
PL182466B1 (pl) 2002-01-31
EP0697019A1 (fr) 1996-02-21
BG62004B1 (bg) 1998-12-30
LV12315A (lv) 1999-07-20
ATE163418T1 (de) 1998-03-15
DE69408666T2 (de) 1998-06-18
NO954275D0 (no) 1995-10-26
CN1121719A (zh) 1996-05-01
LV12315B (en) 2000-03-20
DK0697019T3 (da) 1998-09-28
CZ286688B6 (en) 2000-06-14
FI955166A0 (fi) 1995-10-27

Similar Documents

Publication Publication Date Title
DK0697019T3 (da) Risperidon pamoater
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
NO952321D0 (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
ES2104386T3 (es) Compuesto intermedio para la acitromicina.
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
NO302749B1 (no) Desferrioksamin-B-salter og anvendelse av disse for fremstilling av farmasöytiske sammensetninger
ATE163402T1 (de) Substituierte ortho- ethenylphenylessigsäurederivate
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
DK0632717T3 (da) Middel til anvendelse som et anti-irritationsmiddel
SE9704770D0 (sv) New use
ZA939227B (en) Novel triazoloquinazolines,their preparation and use
FR2700116B1 (fr) Application d'anticonvulsivants comme radioprotecteurs.
NO306673B1 (no) Mellomprodukt for fremstilling av farmasöytisk aktiv forbindelse

Legal Events

Date Code Title Description
MK1K Patent expired